The company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time.
 
Status Suspended
Process STA
ID number 655

Project Team

Project lead Marcia Miller

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
05 July 2017 Suspended, The company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time.
05 July 2017 The Department of Health has asked NICE to conduct a Single Technology Appraisal of NGR-TNF for previously treated advanced malignant pleural Mesothelioma. However, the company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes
21 April 2017 Referral
21 April 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance